Data Manager allows clients to include large, real-world datasets in their customer presentations in an efficient, compliant manner
The ability to analyze and visualize sequence-activity relationships in proteins and peptides added to D360’s biologics toolkit for drug discovery research
The strategic expansion of Certara’s US Access practice provides clients with opportunities to confront increasing drug pricing and reimbursement challenges
PRINCETON, NJ – July 9, 2019 – Certara has formed a new practice area called Certara Global Health (CGH) to focus its technological expertise on helping to achieve equity in health for all people worldwide.
Certara Announces First Recipients of Certara-Monash University Industry Drug Development Fellowships
PRINCETON, NJ – June 25, 2019 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, and Monash University today announced the recipients of the inaugural Certara-Monash University Industry Drug Development Fellowships – Dr. Katrina Hui, Dr. Yu-Wei Lin, and Dr. Zheng Liu.
Certara’s Simcyp PBPK M&S Technology Achieves First FDA Virtual Bioequivalence Approval for ‘Complex’ Generic Drug
PRINCETON, NJ – June 12, 2019 – Certara’s Simcyp®️ physiologically-based pharmacokinetic (PBPK) modeling and simulation technology was used to demonstrate bioequivalence (BE) for the US Food and Drug Administration (FDA) approval of a complex generic drug on the agency’s abbreviated new drug application (ANDA) pathway.
Certara Scientists to Highlight Model-informed Drug Development, PBPK, MBMA and QSP Progress at PAGE 2019
Certara is contributing to 28 sessions, showcasing modeling by its pharmacometricians, systems pharmacologists, and experts in pharmacoeconomics/health economics outcomes research
It is a multi-functional, cloud-based, 21 CFR Part 11 compliant platform for clinical pharmacology, pharmacometrics and clinical operations professionals.
Certara® the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, announced today that it has appointed Dr. William F. Feehery as its new Chief Executive Officer (CEO) and a member of the Certara Board of Directors, effective June 3, 2019.
New executives’ scientific, operational and consulting expertise will support Simcyp’s footprint in drug development and regulatory decision-making.